Full text is available at the source.
Abstract
Prevalence of GLP-1 receptor agonist prescribing increased from 0.2 to 6.4 per 1,000 deliveries predelivery and from 0.3 to 14.6 per 1,000 deliveries postdelivery.
- Significant prescribing change points were identified in June 2022 for the predelivery period and in March 2021 for the postdelivery period.
- The study examined semaglutide and tirzepatide prescribing among pregnant patients in the United States from 2019 to 2024.
- There is a notable increase in the use of GLP-1 receptor agonists during the perinatal period.
- Understanding these prescribing patterns is critical given the rising obesity rates.
Simplified